Anúncio
Anúncio

BTAI

BTAI logo

BioXcel Therapeutics, Inc. Common Stock

2.00
USD
Patrocinado
-0.04
-1.76%
08 de jan., 15:59 UTC -5
Encerrado
exchange

Pós-Mercado

2.00

-0.01
-0.45%

Relatórios de Lucros BTAI

Rácio de surpresa positiva

BTAI separação 14 de 31 últimas estimativas.

45%

Próximo Relatório

Data do Próximo Relatório
25 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$178.50K
/
-$0.83
Mudanças implicadas de Q3 25 (Revenue/ EPS)
+82.14%
/
-61.93%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
-51.23%
/
-76.75%

BioXcel Therapeutics, Inc. Common Stock earnings per share and revenue

On 12 de nov. de 2025, BTAI reported earnings of -2.18 USD per share (EPS) for Q3 25, missing the estimate of -1.20 USD, resulting in a -81.50% surprise. Revenue reached 98.00 mil, compared to an expected 216.75 mil, with a -54.79% difference. The market reacted with a -15.35% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 6 analistas forecast an EPS of -0.83 USD, with revenue projected to reach 178.50 mil USD, implying an diminuir of -61.93% EPS, and aumentar of 82.14% in Revenue from the last quarter.
FAQ
For Q3 2025, BioXcel Therapeutics, Inc. Common Stock reported EPS of -$2.18, missing estimates by -81.5%, and revenue of $98.00K, -54.79% below expectations.
The stock price moved down -15.35%, changed from $2.02 before the earnings release to $1.71 the day after.
The next earning report is scheduled for 25 de mar. de 2026.
Based on 6 analistas, BioXcel Therapeutics, Inc. Common Stock is expected to report EPS of -$0.83 and revenue of $178.50K for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio